CorMedix
CRMD
39 hedge funds and large institutions have $14.4M invested in CorMedix in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 13 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
1.2% less ownership
Funds ownership: 16.07% → 14.86% (-1.2%)
17% less funds holding
Funds holding: 47 → 39 (-8)
21% less capital inflows, than outflows
Capital inflows: $1.08M | Capital outflows: $1.36M
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
93% less call options, than puts
Call options by funds: $87K | Put options by funds: $1.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$314K |
| 2 |
BlackRock Institutional Trust
San Francisco,
California
|
+$200K |
| 3 |
Spot Trading
Chicago,
Illinois
|
+$130K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$119K |
| 5 |
Taurus Asset Management
New York
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paloma Partners
Greenwich,
Connecticut
|
-$264K |
| 2 |
BG
Bollard Group
Boston,
Massachusetts
|
-$204K |
| 3 |
Credit Suisse
Zurich,
Switzerland
|
-$185K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$111K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$94K |
CRMD Hedge Fund Activity: Q3 2016 in Review
39 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2016, worth a combined $14.4M — up 25% from $11.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CRMD and 5 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $314K. The largest seller was Paloma Partners, exiting entirely with an estimated $264K sold.
- 39 institutional investors held CorMedix (CRMD) as of Q3 2016, down from 47 in Q2 2016.
- Funds reported $14.4M of CorMedix stock for Q3 2016, up 25% quarter-over-quarter.
- 5 funds opened new CorMedix positions in Q3 2016 and 13 closed out, a net change of -8 holders.
- The largest CorMedix buyer in Q3 2016 was Vanguard Group, an estimated $314K added.
- The largest CorMedix seller in Q3 2016 was Paloma Partners, an estimated $264K sold.
Based on aggregated 13F filings for Q3 2016.